Search research articles
Contact Us
Filters
Showing results (121-130 of 149) with videos related to
Page
of 15
Sort By:
American Journal of Hematology
|
January 25, 2013
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study
Drorit Merkel, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2015
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome
Yishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Leukemia & Lymphoma
|
September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
Yafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
American Journal of Hematology
|
September 3, 2025
Triple A Plus (AAA<sup>+</sup>) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients
Ayalew Tefferi, Giuseppe G Loscocco, Lior Rokach, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 26, 2022
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Aaron Shengting Mai, Ainsley Ryan Yan Bin Lee, Ryan Yong Kiat Tay, et al.
Hematological Oncology
|
October 31, 2022
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era
Theodoros P Vassilakopoulos, Fotios Panitsas, Zois Mellios, et al.
British Journal of Haematology
|
July 14, 2026
Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study
Tzvika Porges, Tsofia Levi, Eldad J Dann, et al.
Nature Medicine
|
February 23, 2021
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
Yael C Cohen, Mor Zada, Shuang-Yin Wang, et al.
Annals of Hematology
|
January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis
Irit Avivi, Chava Perry, Yafit Segman, et al.
Mycoses
|
September 15, 2019
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study
Rosa Ruchlemer, Ronen Ben-Ami, Maskit Bar-Meir, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 149) with videos related to
Sort By:
Page
of 15
American Journal of Hematology
|
January 25, 2013
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study
Drorit Merkel, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 31, 2015
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome
Yishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Leukemia & Lymphoma
|
September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
Yafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.
American Journal of Hematology
|
September 3, 2025
Triple A Plus (AAA<sup>+</sup>) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients
Ayalew Tefferi, Giuseppe G Loscocco, Lior Rokach, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 26, 2022
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Aaron Shengting Mai, Ainsley Ryan Yan Bin Lee, Ryan Yong Kiat Tay, et al.
Hematological Oncology
|
October 31, 2022
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era
Theodoros P Vassilakopoulos, Fotios Panitsas, Zois Mellios, et al.
British Journal of Haematology
|
July 14, 2026
Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study
Tzvika Porges, Tsofia Levi, Eldad J Dann, et al.
Nature Medicine
|
February 23, 2021
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
Yael C Cohen, Mor Zada, Shuang-Yin Wang, et al.
Annals of Hematology
|
January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis
Irit Avivi, Chava Perry, Yafit Segman, et al.
Mycoses
|
September 15, 2019
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study
Rosa Ruchlemer, Ronen Ben-Ami, Maskit Bar-Meir, et al.
Page
of 15